Cancer Centre

The Cancer Centre provides detection, diagnosis and treatment of the most prevalent cancers in Indonesia including: cervical cancer, breast cancer, colorectal cancer, nasopharyngal cancer, lung cancer, paediatric cancers, leukaemia, liver cancer, prostate cancer, renal cancer and skin cancer.

In recognising the contemporary approach required to prevent and treat the cancers most prevalent in the Indonesian population, the MRCCC makes use of its state-of-the-art medical technology and top specialist doctors to achieve the best outcome for each patient. The most common cancer in Indonesia is cervical cancer, with 300,000 new cases yearly. The Cancer Centre adopts a preventative approach, encouraging regular pap smear tests and the cervical cancer vaccine.

Opening in 2011 and located in the impressive MRCCC building in central Jakarta, the Cancer Centre provides the following diagnostic and therapeutic services:

Diagnostic:

• PET-CT and SPECT-CT Scans: molecular imaging for non-invasive evaluation
• Multi-slice CT Scan 265: uses x-ray to obtain cross-sectional images of the body
• High strength MRI 3 Tesla: uses magnetism and radiowaves to detect abnormalities
• Mammography: low dose amplitude x-ray used as a diagnostic and screening tool to examine the human breast. Used for early diagnosis of breast cancer
• Ultrasonography: ultrasound for diagnostic imaging.
• Angiography: medical imaging, particularly used for arteries, veins and heart

  .
Therapeutic:

• Linear accelerator Rapid ARC: provides a modern, precise way of delivering radiation therapy, using higher doses directed at the tumour. This is Indonesia’s first and only Rapid ARC machine.
• Radionuclide therapy:
• RIT (Radioisotop therapy) – targeted therapy delivered through infusion into the blood stream or ingestion. Can treat thyroid cancer and neuroendocrine tumours.
• Radiopeptide therapy – can be used to treat tumours resistant to chemotherapy, especially progressive neuroendocrine tumours.

Liver GI Centre

Indonesia has the third highest prevalence of Hepatocellular (HCC) liver cancer worldwide. 30 million Indonesians are living with Hepatitis B and Hepatitis C, and 15 million of this group will develop Chronic Liver Disease (CLD). 10% of Indonesians with CLD will develop liver cancer.

Opening in 2011, and located within the MRCCC building, The Liver GI Centre employs Indonesia’s top Internist Gastrohepatologists to work as a cohesive team, providing diagnosis and treatment of the country’s most common liver and GI diseases.

The Centre’s facilities are located on the 23rd and 25th floors, and diagnostic facilities include: Endoscopy, ERCP (combined endoscopy and fluoroscopy) and Imaging.